HK1204294A1 - -{ -{ }- -環丙基- -{ -{ -羥基- -甲基丙基 氧基}- 三氟甲基 嘧啶- -基 氨基}苯基 亞碸亞胺用於治療特定腫瘤的用途 - Google Patents

-{ -{ }- -環丙基- -{ -{ -羥基- -甲基丙基 氧基}- 三氟甲基 嘧啶- -基 氨基}苯基 亞碸亞胺用於治療特定腫瘤的用途

Info

Publication number
HK1204294A1
HK1204294A1 HK15104968.3A HK15104968A HK1204294A1 HK 1204294 A1 HK1204294 A1 HK 1204294A1 HK 15104968 A HK15104968 A HK 15104968A HK 1204294 A1 HK1204294 A1 HK 1204294A1
Authority
HK
Hong Kong
Prior art keywords
sulfoximide
methylpropyl
aminophenyl
pyrimidin
cyclopropyl
Prior art date
Application number
HK15104968.3A
Other languages
English (en)
Inventor
‧科爾納克
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47891732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1204294(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of HK1204294A1 publication Critical patent/HK1204294A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15104968.3A 2012-03-21 2015-05-26 -{ -{ }- -環丙基- -{ -{ -羥基- -甲基丙基 氧基}- 三氟甲基 嘧啶- -基 氨基}苯基 亞碸亞胺用於治療特定腫瘤的用途 HK1204294A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012204506 2012-03-21
PCT/EP2013/055561 WO2013139734A1 (de) 2012-03-21 2013-03-18 Verwendung von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung spezifischer tumore

Publications (1)

Publication Number Publication Date
HK1204294A1 true HK1204294A1 (zh) 2015-11-13

Family

ID=47891732

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104968.3A HK1204294A1 (zh) 2012-03-21 2015-05-26 -{ -{ }- -環丙基- -{ -{ -羥基- -甲基丙基 氧基}- 三氟甲基 嘧啶- -基 氨基}苯基 亞碸亞胺用於治療特定腫瘤的用途

Country Status (20)

Country Link
US (1) US20150051232A1 (zh)
EP (1) EP2827871A1 (zh)
JP (1) JP2015510910A (zh)
KR (1) KR20140135215A (zh)
CN (1) CN104220075A (zh)
AP (1) AP2014007915A0 (zh)
AU (1) AU2013234451A1 (zh)
CA (1) CA2867746A1 (zh)
CL (1) CL2014002472A1 (zh)
EA (1) EA201491732A1 (zh)
HK (1) HK1204294A1 (zh)
MA (1) MA35943B1 (zh)
MX (1) MX2014011240A (zh)
PH (1) PH12014502075A1 (zh)
SA (1) SA113340398B1 (zh)
SG (1) SG11201405386SA (zh)
TN (1) TN2014000391A1 (zh)
TW (1) TW201338779A (zh)
WO (1) WO2013139734A1 (zh)
ZA (1) ZA201406986B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015071231A1 (de) * 2013-11-14 2015-05-21 Bayer Pharma Aktiengesellschaft Kombinationen von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung von tumoren
PL3154594T3 (pl) 2014-06-13 2023-10-09 Bach Biosciences, Llc Środki terapeutyczne aktywowane FAP i związane z nimi zastosowania

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1307271A (en) 1970-06-25 1973-02-14 Shell Int Research Sulphoximine derivatives and their use in herbicidal compositions
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
WO1999002162A1 (en) 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibiting purine derivatives
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
EP1107958B1 (en) 1998-08-29 2006-08-16 AstraZeneca AB Pyrimidine compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
JP4771576B2 (ja) * 2000-06-12 2011-09-14 譲治 稲澤 Ｇａｓｃ１遺伝子
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
WO2002096888A1 (de) 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
AU2003212282A1 (en) 2002-03-11 2003-09-22 Schering Aktiengesellschaft Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament
AU2003276463A1 (en) * 2002-11-06 2004-06-07 Cyclacel Limited Combination comprising a cdk inhibitor and cisplatin
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2179991A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
JP2012509859A (ja) * 2008-11-24 2012-04-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 中皮腫の治療のためのｃｄｋ阻害物質
PT2424843E (pt) * 2009-04-30 2014-06-02 Novartis Ag Derivados de imidazol e seu uso como moduladores de quinases dependentes de ciclina
DE102010014427A1 (de) 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren

Also Published As

Publication number Publication date
CL2014002472A1 (es) 2014-12-12
ZA201406986B (en) 2016-08-31
CN104220075A (zh) 2014-12-17
JP2015510910A (ja) 2015-04-13
KR20140135215A (ko) 2014-11-25
US20150051232A1 (en) 2015-02-19
SA113340398B1 (ar) 2016-04-04
MX2014011240A (es) 2014-10-15
PH12014502075A1 (en) 2014-12-10
CA2867746A1 (en) 2013-09-26
AP2014007915A0 (en) 2014-09-30
TN2014000391A1 (en) 2015-12-21
EA201491732A1 (ru) 2015-08-31
EP2827871A1 (de) 2015-01-28
AU2013234451A1 (en) 2014-09-25
SG11201405386SA (en) 2014-11-27
WO2013139734A1 (de) 2013-09-26
MA35943B1 (fr) 2014-12-01
TW201338779A (zh) 2013-10-01

Similar Documents

Publication Publication Date Title
HK1216025A1 (zh) 用於治療癌症的嘧啶- -二胺衍生物
HK1213883A1 (zh) 取代的嘧啶基和吡啶基吡咯並吡啶酮類、其製備方法及其作為激酶抑制劑的用途
SG2014008304A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
IL236495A0 (en) Heteroaromatic compounds as proton tyrosine kinase inhibitors
HK1206338A1 (zh) 用於治療癌症的嘧啶化合物
HUE037154T2 (hu) Szubsztituált benzilindazol-származékok mint Bub1 kinázgátlók hiperproliferatív megbetegedések kezelésére
HK1204474A1 (zh) 用於治療癌症，自身免疫炎症和中樞神經系統障礙的雙氟二氧戊環氨基苯並咪唑激酶抑制劑
HK1206620A1 (zh) 血脂異常症治療劑
EP2925752A4 (en) PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
IL237976A0 (en) A derivative of 7-azaindole-2,7-naphthyridine for the treatment of tumors
HK1223832A1 (zh) 用於癌症治療的激酶抑制劑
HK1204294A1 (zh) -{ -{ }- -環丙基- -{ -{ -羥基- -甲基丙基 氧基}- 三氟甲基 嘧啶- -基 氨基}苯基 亞碸亞胺用於治療特定腫瘤的用途
HK1211229A1 (zh) -{ -{ }- -環丙基- -{ -{ -羥基- -甲基丙基 氧基}- 三氟甲基 嘧啶- -基 氨基}苯基 亞碸亞胺用於治療特定腫瘤的用途
PT2777699T (pt) Dietilamina-2,5-di-hidroxibenzenossulfonato para o tratamento de degeneração macular relacionada com a idade
IL232339A0 (en) 32rf10c antibodies, and their uses for cancer treatment
PT2925744T (pt) Derivados de pirimidina-2,4-diamina para tratamento de cancro
GB201222546D0 (en) Novel compounds and improved treatments for glaucoma